Cemiplimab in cSCC Updated Data

Cemiplimab in cSCC Updated Data

obr

4 months
108 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Danny Rischin, MD, Division of Cancer Medicine, Department of Medical Oncology, Peter MacCallum Cancer Centre, Professor of Medicine, University of Melbourne discusses the updated data for the treatment of cutaneous squamous cell carcinoma (cSCC).
Up Next Autoplay
Taking Baby Aspirin Improves  Overall Survival for Patients: What's Next For Research?
Taking Baby Aspirin Improves Overall Survival for Patients: What's Next For Research?
Category: Head and Neck Cancers
6 Views
Cancer-News 1 month
Why Is There No Benefit To Cancer Specific Survival?
Why Is There No Benefit To Cancer Specific Survival?
Category: Head and Neck Cancers
7 Views
Cancer-News 1 month
Taking Baby Aspirin Improves Overall Survival for Patients
Taking Baby Aspirin Improves Overall Survival for Patients
Category: Head and Neck Cancers
22 Views
Cancer-News 1 month
Taking Baby Aspirin Improves Overall Survival for Patients With Head & Neck, Lung Cancer
Taking Baby Aspirin Improves Overall Survival for Patients With Head & Neck, Lung Cancer
Category: Head and Neck Cancers
17 Views
Cancer-News 2 months
Importance of Stratification by PD-L1 Score
Importance of Stratification by PD-L1 Score
Category: Head and Neck Cancers
58 Views
obr 4 months
Thoughts on KEYNOTE-048
Thoughts on KEYNOTE-048
Category: Head and Neck Cancers
89 Views
obr 4 months
LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA
LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA
Category: Head and Neck Cancers
16 Views
Annual-Meeting 5 months
Primary analysis of Phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).
Primary analysis of Phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).
Category: Head and Neck Cancers
308 Views
Annual-Meeting 5 months
Who Should Get Monotherapy Or Pembrolizumab Combo: Reasonable To Use Pembrolizumab Monotherapy In Patients That Have CPS Greater Than 20
Who Should Get Monotherapy Or Pembrolizumab Combo: Reasonable To Use Pembrolizumab Monotherapy In Patients That Have CPS Greater Than 20
Category: Head and Neck Cancers
44 Views
Annual-Meeting 5 months